The Supreme Court Just Closed the Courthouse Door on Thousands of Pesticide Cancer Lawsuits — What Happens Now
If you are reading this page, you are probably one of two people. You are someone who developed non-Hodgkin lymphoma after years of using Roundup, or someone whose father or husband shakes now because he sprayed paraquat on the fields for a decade — and you had a lawsuit pending, or were about to file one. You just learned the Supreme Court ruled against the legal theory your case was built on. The news hit like a second diagnosis. We are going to tell you the truth about what this ruling means, what may still survive, and what to do in the days ahead — because the truth, even when it is hard, is what protects you.
We are Attorney911 — The Manginello Law Firm, PLLC. We are toxic tort lawyers. We handle the cases where a corporation put a chemical into the world, people got sick, and the company spent a decade pretending it didn’t know. This page is our honest, practitioner-level analysis of what the Supreme Court just did in Monsanto v. Durnell, what it means for every pending Roundup and paraquat case in the country, and what legal ground — if any — remains for the people the ruling left behind. We are not going to sugarcoat this. We are also not going to tell you it is over, because for some of you, it is not.
The Ruling in Plain English: What the Supreme Court Held
On June 25, 2026, the United States Supreme Court ruled 7-2 that a federal pesticide law called the Federal Insecticide, Fungicide, and Rodenticide Act — known as FIFRA — expressly preempts state-law failure-to-warn claims against pesticide manufacturers when the Environmental Protection Agency has not required the specific warnings those lawsuits demand. Justice Brett Kavanaugh wrote the majority opinion. Justice Ketanji Brown Jackson wrote the dissent, joined by Justice Neil Gorsuch.
Here is what that means in human language. For nearly a decade, more than 100,000 people sued Monsanto — now owned by Bayer — claiming that Roundup’s active ingredient, glyphosate, caused their non-Hodgkin lymphoma, and that Monsanto knew about the cancer risk and failed to put a warning on the label. Every one of those cases was built on the same legal foundation: the company should have warned you. The Supreme Court just pulled that foundation out.
The majority’s reasoning goes like this: FIFRA gives the EPA authority over pesticide labels. The EPA reviewed glyphosate and concluded it is “not likely” to be carcinogenic. Because the EPA did not require a cancer warning on Roundup’s label, a state jury cannot hold Monsanto liable for failing to add one — because doing so would effectively require a pesticide label “different from” what the EPA approved, which FIFRA’s express preemption clause forbids.
The case was Monsanto v. Durnell, and the specific legal question was whether FIFRA’s preemption provision bars state tort claims alleging a company failed to warn users of product risks when the EPA itself has not required such warnings. The Court answered yes.
“Fifra expressly preempts Durnell’s state-law failure-to-warn claim.”
— Justice Brett Kavanaugh, majority opinion, Monsanto v. Durnell (June 25, 2026)
That one sentence is the reason several thousand pending Roundup lawsuits and several thousand pending paraquat Parkinson’s disease lawsuits now face dismissal — unless the lawyers representing those plaintiffs can find a different legal theory that the ruling did not touch.
Why FIFRA Preemption Works the Way It Does — and Why It Just Swallowed Your Case
To understand what just happened, you need to understand the architecture of federal pesticide law. FIFRA is a federal statute that requires every pesticide sold in the United States to be registered with the EPA. As part of that registration, the EPA reviews the product’s chemistry, toxicology, and proposed labeling. The agency decides what warnings must appear on the label — and what warnings need not appear. Once the EPA approves a label, that label becomes the federally sanctioned set of requirements for that product.
FIFRA also contains an express preemption clause. Under 7 U.S.C. § 136v(b), states “shall not impose or continue in effect any requirements for labeling or packaging in addition to or different from those required under this Act.” This language has been in the statute for decades. The question the Supreme Court just answered is what that clause actually means when a plaintiff walks into a state court and says: “Monsanto should have warned me that Roundup causes cancer, and because it didn’t, I got non-Hodgkin lymphoma.”
The majority said: that state-law duty to warn is a “requirement for labeling” that is “in addition to or different from” what the EPA required — because the EPA specifically decided not to require a cancer warning. Therefore, the state claim is expressly preempted. The state cannot impose a labeling requirement the federal government chose not to impose.
Bayer argued exactly this. The company said: under FIFRA, the EPA is the key authority for determining whether a product requires a cancer warning. The EPA has not required one. The EPA’s position is that glyphosate is “unlikely” to be carcinogenic. Therefore, the company cannot be held liable for failing to warn about a risk the federal regulator said does not rise to the level requiring a label change. The Supreme Court agreed.
The Dissent: Justice Jackson’s Warning That the Majority Left the Injured Without Any Remedy
Justice Jackson’s dissent is the roadmap for anyone who believes this ruling was wrong — and it may also be the roadmap for future legislative or regulatory reform. She was joined by Justice Gorsuch, an unlikely pairing that itself signals how strange the preemption landscape has become.
“Fifra expressly limits States’ authority to regulate pesticide labels, but it does not eliminate that authority. Fifra’s preemption clause does not block state-law claims where the violation of state law is also a violation of Fifra.”
— Justice Ketanji Brown Jackson, dissenting opinion, Monsanto v. Durnell (June 25, 2026)
The dissent’s core argument is that FIFRA’s preemption clause was never meant to be a one-way shield for manufacturers. Jackson argued that FIFRA limits state labeling authority but does not eliminate it — and critically, that preemption should not block state-law claims where the alleged violation of state law is also a violation of FIFRA itself. This is the “parallel claims” theory: if a plaintiff can show that the company violated both state law and federal FIFRA requirements simultaneously, the state claim should survive because it is not imposing a “different” requirement — it is enforcing the same one.
“In accepting Monsanto’s argument and holding that Durnell’s failure-to-warn claim is preempted, the Court misunderstands Fifra’s requirements, misinterprets the scope of Fifra’s preemption, and ultimately leaves Durnell without a remedy for the significant harms he has suffered.”
— Justice Ketanji Brown Jackson, dissenting opinion
That last phrase — “leaves Durnell without a remedy for the significant harms he has suffered” — is the human cost of the ruling in one sentence. A man who alleges he got cancer from a product the manufacturer sold for decades, and whose own international cancer authority classified the active ingredient as a probable human carcinogen, now has no legal avenue to hold that manufacturer accountable for failing to warn him — because a federal agency decided the cancer risk wasn’t serious enough to require a label.
What This Means for Pending Roundup Non-Hodgkin Lymphoma Cases
The Roundup litigation has been coordinated through a federal multidistrict litigation proceeding — MDL-2741, In re: Roundup Products Liability Litigation, before Judge Vince Chhabria in the Northern District of California. As of mid-2026, approximately 3,900 actions were pending in the MDL, with additional cases in state courts across the country. Bayer has spent the better part of a decade fighting more than 100,000 lawsuits filed by people who developed non-Hodgkin lymphoma they blame on glyphosate exposure, and the company has paid out billions in jury awards and settlements.
All of those cases — every one — included allegations that Monsanto failed to warn that glyphosate could cause cancer. That theory is now expressly preempted under FIFRA where the EPA has not required such warnings. The immediate consequence is that the failure-to-warn claims included in several thousand pending Roundup lawsuits cannot go forward.
Bayer said as much in its own statement, which described the ruling as one that “should result in the dismissal of current warning-based claims and bar future failure-to-warn claims.” That is not corporate spin — that is an accurate reading of what the majority held.
But “dismissal of warning-based claims” is not the same as “dismissal of every claim.” And this is where the fight shifts — not ends.
What This Means for Paraquat Parkinson’s Disease Cases
The ruling’s reach extends beyond Roundup. Thousands of similar failure-to-warn claims are pending against Syngenta, the manufacturer of paraquat dichloride, a restricted-use herbicide that has been scientifically linked to Parkinson’s disease. Those cases are coordinated in a separate federal MDL — MDL-3004, In re: Paraquat Products Liability Litigation, before Chief Judge Nancy J. Rosenstengel in the Southern District of Illinois. Approximately 6,600 actions were pending as of mid-2026.
The paraquat cases face the same preemption wall: the EPA has not required a Parkinson’s disease warning on paraquat labels, and Syngenta maintains the evidence linking paraquat to Parkinson’s is “fragmentary” and “inconclusive.” Under the Durnell reasoning, state-law failure-to-warn claims seeking a Parkinson’s warning the EPA chose not to require are now preempted.
But paraquat plaintiffs face a second threat that Roundup plaintiffs do not: the general-causation fight in the paraquat MDL has been scientifically contested, with the defense challenging the plaintiffs’ expert evidence on whether paraquat actually causes Parkinson’s disease at all. The preemption ruling and the Daubert causation fight together create a double barrier — preemption closes the warning door, and contested science threatens the causation door.
This is the honest terrain for paraquat plaintiffs: the primary legal theory is now blocked by preemption, and the underlying scientific link — while supported by multiple epidemiological studies — has been challenged in court. Any surviving paraquat case needs both a non-preempted legal theory and a rock-solid specific-causation expert.
Legal Theories That May Survive the Preemption Ruling
This is the section that matters most for anyone with a pending case or a contemplated filing. The Supreme Court ruled on failure-to-warn claims. It did not rule on every product-liability theory. The question now is which alternative theories can survive preemption scrutiny — and that question will be litigated in federal and state courts across the country for years.
Design defect. A design-defect claim argues that the product is unreasonably dangerous in its formulation or composition — regardless of what the label says. This is not a claim about what the label should have said. It is a claim about what the product should have been. If a plaintiff can argue that glyphosate-based Roundup, or paraquat dichloride, is unreasonably dangerous as designed — that a safer alternative design existed and the manufacturer chose not to use it — that claim may not be preempted by FIFRA’s labeling-specific preemption clause. The critical distinction: a design-defect claim must be framed independently of labeling requirements. The moment it collapses into “the product was dangerous and the label should have said so,” it becomes a repackaged failure-to-warn claim and dies under Durnell. Courts will scrutinize these pleadings carefully. A design-defect claim that is merely a warning claim in disguise will not survive.
Negligent testing and research. A claim that the manufacturer negligently conducted — or failed to conduct — adequate safety testing could potentially survive if it is not dependent on label content and is not tantamount to a failure-to-warn claim. The theory would be: the company had a duty to test its product for carcinogenicity, it conducted that testing negligently or not at all, and that negligence caused the plaintiff’s injury because the product reached the market with an unreasonably dangerous risk profile. This is a claim about the company’s research conduct, not about what the label said. But the defense will argue that any negligent-testing claim that would require a different label as a remedy is still preempted — and some courts may agree.
Breach of implied warranty of merchantability. This theory may survive in limited form if it is predicated on a product defect — the product was not fit for its ordinary purpose because it was unreasonably dangerous — rather than on a label deficiency. But courts will examine whether the warranty claim is simply a failure-to-warn claim wearing a different label. If the warranty theory depends on the argument that the product was unmerchantable because it lacked an adequate warning, it is preempted.
The “parallel claim” theory from the dissent. Justice Jackson’s dissent offered a framework that future plaintiffs may try to invoke: state-law claims that parallel rather than add to FIFRA requirements should not be preempted. If a plaintiff can identify a specific FIFRA requirement the manufacturer violated — not just a state-law duty that differs from federal requirements — the state claim may survive. This theory was rejected by the majority in Durnell as applied to the failure-to-warn claim at issue, but the dissent’s framework could be tested in future cases involving different types of claims.
The honest assessment: these surviving theories face serious obstacles. The factual record in most pending cases was built around failure-to-warn. Expert witnesses were deposed on warning adequacy. Discovery was conducted on what the company knew and when it should have warned. Recharacterizing these cases under design-defect or negligent-testing theories requires amended complaints, new expert opinions, and a factual record that may not fully support the alternative theory. This is the triage work that every plaintiff’s lawyer in the Roundup and paraquat MDLs is now doing — and it takes time.
The Regulatory Conflict at the Heart of This Case: EPA vs. WHO on Glyphosate
The Durnell ruling does not exist in a scientific vacuum. It exists in the middle of a genuine, unresolved conflict between two authoritative bodies about whether glyphosate causes cancer.
The EPA has consistently taken the position that glyphosate is “not likely” to be carcinogenic to humans. The agency’s registration reviews have repeatedly concluded that glyphosate does not require a cancer warning on product labels. This is the regulatory position the Supreme Court majority relied on — the EPA looked at the science and decided a cancer warning was not necessary.
But in 2015, the International Agency for Research on Cancer — IARC, which is an arm of the World Health Organization — classified glyphosate as a “probable human carcinogen” (Group 2A). That classification was based on a review of the available scientific evidence, including epidemiological studies of exposed workers and laboratory evidence of genotoxicity. IARC’s conclusion has been the scientific spine of the plaintiffs’ cases — if the world’s leading cancer authority says glyphosate is probably carcinogenic, how can a manufacturer claim it had no duty to warn?
The Supreme Court’s ruling effectively converts the EPA’s contrary position into a preemption shield. The agency said no warning was needed — and the Court said that determination blocks state courts from concluding otherwise. The dissent’s objection, in essence, is that the EPA’s scientific judgment should not be the sole determinant of a manufacturer’s duty to warn — especially when another authoritative body reached the opposite conclusion.
This regulatory conflict is not going away. It is the scientific fault line under the entire litigation, and it is the reason the ruling feels so unjust to the people it affects: a federal agency declined to require a warning, and the Court used that inaction to shield the manufacturer from the people who got sick.
As environmental and public health groups noted in their responses to the ruling, the fact that the EPA approved a pesticide label does not mean the product is safe — and it should not become a shield for companies that fail to warn about cancer risks, neurological harm, and other serious dangers. That argument is now a matter for Congress and future regulatory reform, not the courts that are bound by the Supreme Court’s holding.
The Medicine: What Non-Hodgkin Lymphoma and Parkinson’s Disease Actually Do to a Human Being
Behind every lawsuit in these MDLs is a person whose body was changed by a disease they believe was caused by a chemical they were never warned about. The damages in these cases are catastrophic — not because lawyers inflate them, but because the medicine is catastrophic.
Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma is a cancer that originates in the lymphatic system, part of the body’s immune defense. It arises when lymphocytes — a type of white blood cell — develop mutations that cause them to multiply uncontrollably and fail to die on their normal schedule. The diseased cells accumulate in lymph nodes, spleen, bone marrow, and other lymphoid tissue, producing painless swellings that are often the first sign something is wrong.
The treatment depends on the subtype and stage, but it is brutal. Diffuse large B-cell lymphoma — the most common aggressive subtype — is typically treated with R-CHOP chemotherapy, a five-drug regimen that includes rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, given in cycles every three weeks for approximately six cycles. Side effects include severe immunosuppression, nausea, hair loss, cardiac toxicity from doxorubicin, and peripheral neuropathy from vincristine. For patients who relapse, treatment escalates to high-dose chemotherapy followed by autologous stem cell transplant — a process that involves harvesting the patient’s own stem cells, giving near-lethal doses of chemotherapy to wipe out the bone marrow, and reinfusing the stem cells to rebuild the blood system from scratch. Some patients require allogeneic transplants from donors, which adds graft-versus-host disease to the list of risks.
The economic cost of NHL treatment — chemotherapy, biologic drugs, imaging, hospitalization, stem cell transplant, years of surveillance — runs into the hundreds of thousands of dollars and can exceed a million dollars for patients who undergo transplant. The human cost — the fear, the nausea, the lost work, the strain on a marriage, the years stolen — cannot be measured on a hospital bill.
Parkinson’s Disease
Parkinson’s disease is a progressive neurodegenerative disorder that destroys dopamine-producing neurons in the substantia nigra, a region deep in the brain. Dopamine is the neurotransmitter that controls voluntary movement. As those neurons die, the body loses its ability to initiate and control motion smoothly.
The disease announces itself gradually. A tremor in one hand. A stiffness that won’t release. A gait that slows and shuffles. A handwriting that shrinks. Over years — sometimes decades — the symptoms worsen. The tremor spreads. Balance fails. Falls begin. The face becomes a mask, showing no expression. Speech softens to a whisper. Swallowing becomes difficult and dangerous.
There is no cure. Treatment is symptomatic. Levodopa, the gold standard since the 1960s, replaces the missing dopamine — but it does not stop the underlying neuron death, and after years of use, its effectiveness wanes while its side effects, including involuntary movements called dyskinesias, grow worse. Deep brain stimulation — implanted electrodes that deliver electrical pulses to specific brain regions — can help some patients but is brain surgery, with all the risk that entails.
The non-motor symptoms are equally devastating: cognitive decline progressing to dementia in many patients, depression, anxiety, sleep disorders, autonomic dysfunction causing blood pressure swings and bowel and bladder problems. A person with Parkinson’s may live 10 to 20 years after diagnosis, and in those years, the life they knew narrows — from independent to assisted to wheelchair-bound to bed-bound, while the mind that was once sharp watches the body fail around it.
The lifetime cost of Parkinson’s care — medications, neurology visits, physical and occupational therapy, fall-related hospitalizations, eventual assisted living or nursing home care, and the lost income from a working life cut short — is enormous. A wrongful death claim built around a Parkinson’s death must account for decades of progressive disability and care.
What Your Case Is Worth Now — An Honest Valuation
We are not going to give you a number and pretend it is what your case is worth, because the ruling just changed the math for every pending case. Here is the honest valuation framework.
For pure failure-to-warn claims: The realistic near-term value approaches zero. These claims face dismissal under the ruling. If your case relies solely on the theory that the manufacturer failed to warn you of cancer or Parkinson’s risks, and the EPA did not require such a warning, your claim is now preempted. This is the hard truth the ruling imposed, and any lawyer who tells you otherwise without explaining the preemption analysis is not being straight with you.
For claims that survive on non-preempted theories: If your case can be recharacterized under a design-defect theory, a negligent-testing theory, or another non-warning claim that survives preemption scrutiny, and if you have documented catastrophic injuries with strong specific causation evidence against a deep-pocket defendant like Bayer, the potential value range is significant — in the range of $1 million to $10 million or more for cases with severe injuries, strong exposure histories, and clean alternative-cause profiles. But the path to recovery is now extraordinarily uncertain, and the universe of viable claims has contracted dramatically.
For settlement leverage: The ruling reduces settlement leverage significantly. Before Durnell, the threat of a plaintiff verdict on failure-to-warn claims drove Bayer’s multi-billion-dollar settlement posture. That threat is now diminished for the warning-based claims that remain pending. Bayer’s settlement posture will likely harden, and cases that previously carried settlement value based on warning-claim trial risk may see that value contract. However, cases with strong specific causation, severe injuries, and viable alternative theories may still carry settlement value if those theories present any trial risk to the company.
Prior verdicts and settlements: Before this ruling, Roundup verdicts and settlements reached multi-million-dollar and in some cases nine-figure ranges, though many were reduced on appeal. Those results were achieved under the legal framework that the Supreme Court has now altered. They are not predictive of what surviving cases will yield, and we will not cite specific prior verdict figures as if they represent what your case is worth now. Past results depend on the facts of each case and do not guarantee future outcomes.
The Evidence You Still Need to Preserve — and How Fast It Can Disappear
If your case may survive on a non-preempted theory, the evidence that supports it is just as critical as it was before the ruling — and in some ways more so, because the factual record for a design-defect or negligent-testing claim is different from the record for a failure-to-warn claim.
Medical records and pathology reports. Your non-Hodgkin lymphoma subtype or Parkinson’s disease diagnosis, with a documented temporal relationship to your exposure, should already be in your counsel’s possession. Ensure the record is complete — every pathology report, every imaging study, every treatment note. For NHL, the subtype matters (diffuse large B-cell versus follicular versus others) because some subtypes have stronger epidemiological links to glyphosate. For Parkinson’s, the diagnostic workup — including response to levodopa, brain imaging to exclude other causes, and the clinical course — establishes the specific injury.
Detailed exposure history. Purchase records, usage logs, application frequency, duration of use, and protective equipment use are critical for establishing a dose-response relationship and specific causation independent of any labeling theory. This evidence is the foundation of a surviving design-defect claim: you must prove not just that the product was dangerous, but that you were exposed to enough of it for long enough to cause your specific disease. Witness memory fades. Retail records are destroyed on routine cycles. Agricultural use records may be maintained by state agencies but are not permanent. Preserve this evidence before it disappears.
Internal corporate documents on toxicity research and regulatory submissions. Extensive discovery has already been produced in the Roundup and paraquat MDLs — internal emails, research memos, regulatory submissions, ghostwriting allegations, and scientific-integrity disputes. These documents support non-preempted theories (negligent testing, design defect) and potential punitive damages if misconduct in research design is shown independent of labeling decisions. Ensure complete copies are maintained as the litigation shifts to alternative theories. These documents are the proof that the company knew — or should have known — that its product was dangerous, regardless of what the label said.
EPA registration dockets, scientific reviews, and the IARC monograph. These are public records. They document the regulatory and scientific conflict that underpins both the preemption analysis and any remaining design-defect causation evidence. There is no spoliation risk for public records, but ensure current versions are maintained for expert testimony.
The Insurance Playbook: How Bayer and Syngenta Will Use This Ruling
The corporate defendants and their insurers have a playbook, and it just got a new first chapter. Here are the plays you should expect — and the counter to each.
Play 1: Move to dismiss every failure-to-warn claim. Bayer and Syngenta will file motions to dismiss or for summary judgment on every pending failure-to-warn claim, citing Durnell as controlling authority. They will argue that the ruling forecloses all state-law warning claims where the EPA declined to require the warning. The counter: oppose the motions with a simultaneous motion to amend the complaint to add non-preempted theories — design defect, negligent testing — that are not barred by the ruling. The amended complaint must scrub all labeling-dependent allegations and must be supported by a factual record that genuinely supports the alternative theory.
Play 2: Point to the EPA’s scientific position as the authoritative determination. The defendants will argue that the EPA’s conclusion that glyphosate is “not likely” to be carcinogenic should be treated as the definitive scientific judgment, and that any contrary state-law claim is not just preempted but scientifically baseless. The counter: the IARC classification as a probable human carcinogen is an independent, authoritative scientific assessment. Expert witnesses can testify about the epidemiological evidence linking glyphosate to NHL and the biological mechanisms of genotoxicity. The EPA’s regulatory determination is not the same as a scientific consensus — it is one agency’s risk-management decision, made in a regulatory process that the company itself influenced.
Play 3: Harden settlement posture and lowball remaining cases. With the primary trial threat diminished, the companies will offer less to settle — or offer nothing. They will calculate that plaintiffs’ attorneys cannot afford to take weakened cases to trial on uncertain alternative theories. The counter: cases with the strongest specific causation, the most severe injuries, and the cleanest exposure histories still present trial risk on design-defect theories — particularly in jurisdictions with strong product-liability doctrine. A well-prepared design-defect case with a credible alternative-design expert and a compelling corporate-misconduct narrative can still pose a meaningful threat at trial.
Play 4: Attack specific causation. Even on surviving theories, the defense will argue that the plaintiff cannot prove their specific cancer or Parkinson’s was caused by the product rather than by other risk factors — age, genetics, other chemical exposures, lifestyle factors. The counter: a board-certified toxicologist or oncologist who can perform a differential diagnosis, ruling out other causes and tying the specific disease to the documented exposure, is essential. The exposure history — how much, how often, how long — is the foundation of specific causation and must be documented as thoroughly as possible.
How a Surviving Case Is Actually Built
If your case is going to survive, it will be because your lawyer did the following work — and did it thoroughly.
Step 1: Triage. Every pending failure-to-warn case must be evaluated for recharacterization under non-preempted theories. This is not a rubber-stamp process. It requires a candid assessment of whether the factual record — the exposure history, the corporate documents already produced, the medical evidence — supports a design-defect or negligent-testing claim independent of the labeling theory. Some cases will not survive this assessment, and an honest lawyer will tell you that.
Step 2: Amend the complaint. For cases that can be recharacterized, an amended complaint must be filed that scrubs all labeling-dependent allegations. Every paragraph that says “the company failed to warn” must be replaced with a paragraph that says “the product was unreasonably dangerous as designed” or “the company negligently failed to test.” The amended complaint must stand on its own as a non-warning theory — because if it reads like a warning claim in disguise, the court will see through it and dismiss it.
Step 3: Engage or re-depose expert witnesses. Experts must opine on product dangerousness and causation without relying on the warning framework the Supreme Court has foreclosed. A toxicologist who previously testified about warning adequacy must now testify about design dangerousness — a different question that requires a different analytical framework. This may require new expert reports, new depositions, and new Daubert challenges.
Step 4: Build the trial record. In jurisdictions with strong design-defect doctrine, plaintiff firms should test the boundaries of the preemption ruling by building a trial-ready record on non-warning theories. Some states apply a risk-utility test for design defects; others apply a consumer-expectations test. The interplay between FIFRA preemption and these non-warning theories will be litigated in state and federal courts going forward — and the first cases that successfully navigate this terrain will establish the precedent for the rest.
Step 5: Mediation with realistic expectations. Bayer’s settlement posture will likely harden given the ruling’s broad preemption holding. But cases with strong specific causation and severe injuries may still carry settlement value if alternative theories present any trial risk. Mediation should be approached with eyes open — not with the expectation that the pre-Durnell settlement landscape still exists.
The Statute of Limitations: The Clock Is Still Running
For surviving claims — design defect, negligent testing — the statute of limitations is still a live concern, and it varies by state. Most states have personal-injury statutes of limitations ranging from one to six years, with two and three years being the most common.
In toxic tort cases, most states apply some form of the discovery rule: the clock does not start running on the date of exposure. It starts running when the plaintiff discovered — or by reasonable diligence should have discovered — the injury and its causal connection to the exposure. For a Roundup plaintiff diagnosed with non-Hodgkin lymphoma in 2020, the clock likely started around the date of diagnosis, not the date they first sprayed Roundup in 1998.
But this is not universal. Some states have statutes of repose that impose an outer deadline regardless of when the injury was discovered. The discovery rule does not defeat a repose statute. And the specific formulation of the discovery rule — whether it requires knowledge of the injury alone, or knowledge of both the injury and its causal link to the specific product — varies by jurisdiction.
If you are contemplating a new filing based on a non-preempted theory, you must confirm the controlling statute of limitations and any repose statute in your state immediately. The ruling does not extend any deadline. If your SOL has run, no legal theory — preempted or not — will save your case.
What to Do Right Now: Your Next Steps
If you have a pending Roundup or paraquat case, here is what should happen in the days and weeks ahead.
Contact your current lawyer. If you are already represented, your lawyer should be communicating with you about how the ruling affects your specific case. You should receive a candid assessment — not a form letter, not a generic “we’re evaluating the situation” — of whether your case can proceed on alternative theories. If your lawyer cannot tell you within a reasonable timeframe whether your case survives, you may need a second opinion.
If you are not yet represented but were planning to file. The calculus has changed. A failure-to-warn claim is now preempted. Any new filing must be built from the ground up on non-preempted theories. This requires a lawyer who understands the preemption landscape and can build a design-defect or negligent-testing case from scratch — not simply file the same complaint that would have worked before June 25, 2026.
Preserve your evidence. Regardless of your case’s status, ensure that your medical records, exposure history documentation, and any product purchase or usage records are preserved. Memory fades. Retail records are destroyed. The evidence that connects your disease to your exposure is the foundation of any surviving claim.
Do not sign anything from the defendant or its insurer. If Bayer, Syngenta, or any representative of those companies contacts you with a settlement offer or a release to sign — especially now, when they know the ruling has weakened many plaintiffs’ positions — do not sign anything without consulting a lawyer. A quick check with a release printed on it is the oldest play in the insurance playbook, and it is designed to close your case for pennies before you understand what your remaining rights are worth.
Call us. The consultation is free. We will tell you honestly whether we believe your case can survive on alternative theories, and if it cannot, we will tell you that too. We do not take cases we cannot win. We also do not abandon people whose cases have been hurt by a ruling they had no control over — if there is a path forward, we will find it. Call 1-888-ATTY-911. We have live staff 24 hours a day, seven days a week. Not an answering service — people who can start the conversation now.
Frequently Asked Questions
Is my Roundup lawsuit dead because of the Supreme Court ruling?
If your case relies solely on a failure-to-warn theory — the claim that Monsanto should have warned you that Roundup causes cancer — then yes, that specific claim is now preempted under the Supreme Court’s ruling in Monsanto v. Durnell. However, your case may survive on alternative legal theories that the ruling did not address, such as design defect or negligent testing. Whether your specific case can be recharacterized depends on the facts of your exposure, your medical evidence, and the jurisdiction where your case is filed. You need a lawyer to evaluate your individual case — do not assume it is dead until a qualified attorney has reviewed it.
What did the Supreme Court actually decide in Monsanto v. Durnell?
The Court held, 7-2, that FIFRA — the federal pesticide law — expressly preempts state-law failure-to-warn claims against pesticide manufacturers when the EPA has not required the specific warnings those claims seek. Because the EPA determined glyphosate is “not likely” to be carcinogenic and did not require a cancer warning on Roundup’s label, state courts cannot hold Monsanto liable for failing to add one. Justice Kavanaugh wrote the majority opinion. Justice Jackson dissented, joined by Justice Gorsuch, arguing the majority left injured plaintiffs without any remedy.
Does the ruling affect paraquat Parkinson’s disease cases too?
Yes. The same FIFRA preemption logic applies to the paraquat cases against Syngenta. The EPA has not required a Parkinson’s disease warning on paraquat labels, so state-law failure-to-warn claims seeking such a warning are now preempted. Paraquat plaintiffs face the additional challenge of contested general causation — the scientific link between paraquat and Parkinson’s has been challenged in the MDL proceedings. Any surviving paraquat case needs both a non-preempted legal theory and a strong specific-causation expert.
What legal theories can still survive after this ruling?
The ruling addressed failure-to-warn claims specifically. It did not address design defect, negligent testing, or breach of implied warranty theories — though courts will now scrutinize whether those theories are genuinely independent of labeling or are merely repackaged failure-to-warn claims. A design-defect claim argues the product is unreasonably dangerous in its formulation regardless of the label. A negligent-testing claim argues the manufacturer failed to conduct adequate safety research. Both may survive if they are not dependent on label content and can be supported by the factual record.
How long do I have to file a lawsuit?
The statute of limitations varies by state, typically ranging from one to six years for personal injury claims. In toxic tort cases, most states apply a discovery rule — the clock starts when you discovered or should have discovered your injury and its connection to the exposure, not when you were first exposed. Some states also have statutes of repose that impose an outer deadline. The ruling does not extend any deadline. You must confirm the specific deadline in your state immediately.
Can I still settle my case after the ruling?
Settlement is still possible, but the terms have likely changed. The ruling reduces the trial threat that drove Bayer’s pre-ruling settlement posture, so the company will likely offer less — or offer nothing — for cases that previously carried settlement value based on warning-claim trial risk. However, cases with strong specific causation, severe injuries, and viable alternative theories may still carry settlement value if those theories present any trial risk. Do not accept any settlement offer without consulting a lawyer who understands the post-ruling landscape.
What if I already settled my Roundup case — does the ruling affect me?
If your case has already been settled and the settlement is final, the ruling does not reopen or change your settlement. The ruling affects pending and future cases, not resolved ones. If you signed a release as part of a settlement, that release is binding regardless of the Supreme Court’s subsequent ruling.
Was glyphosate actually proven to cause cancer?
The scientific evidence is contested between authoritative bodies. The International Agency for Research on Cancer — IARC, an arm of the World Health Organization — classified glyphosate as a “probable human carcinogen” (Group 2A) in 2015 based on epidemiological studies and laboratory evidence of genotoxicity. The EPA has consistently taken the position that glyphosate is “not likely” to be carcinogenic to humans. Multiple peer-reviewed studies have found associations between glyphosate exposure and non-Hodgkin lymphoma, while others have not. The scientific debate is genuine — which is part of what makes the preemption ruling so painful for plaintiffs: the EPA’s regulatory determination, made in a process the company influenced, now shields the manufacturer from state-court claims even though another authoritative body reached the opposite scientific conclusion.
Should I contact a lawyer now or wait to see how the law develops?
Contact a lawyer now. The statute of limitations is still running in every state. Evidence is still degrading. And the lawyers who are working on these cases right now are the ones who will shape how the surviving theories are litigated — the first cases that successfully navigate the post-Durnell landscape will establish the precedent for everyone else. Waiting to see how the law develops is how a viable claim dies on a deadline.
If I lost a family member to non-Hodgkin lymphoma or Parkinson’s, can their case still go forward?
If a family member who had a pending case has died, the case may continue as a wrongful death or survival action, depending on state law. The personal representative of the estate is typically the person authorized to bring the claim. The preemption ruling affects wrongful-death failure-to-warn claims the same way it affects living plaintiffs’ claims — the warning theory is preempted, but alternative theories may survive. The deadline for filing a wrongful-death claim is typically shorter than the personal-injury deadline and runs from the date of death. Contact a wrongful death attorney immediately if this is your situation.
Why This Firm
We are Attorney911 — The Manginello Law Firm, PLLC. We are based in Houston, Texas, and we take toxic tort, catastrophic injury, and wrongful death cases. We are writing to you as the firm we are, not the firm we wish we were.
Ralph P. Manginello is our managing partner. He has been licensed to practice law in Texas since November 6, 1998 — 27+ years. He is admitted to the United States District Court for the Southern District of Texas, including its Bankruptcy Court. Before he was a lawyer, Ralph was a journalist. That training matters in a toxic tort case because the evidence these cases turn on — internal corporate documents, scientific studies, regulatory filings — is the same kind of material a journalist learns to read, interrogate, and explain to people who do not have a PhD. Ralph went to South Texas College of Law Houston for his J.D. and the University of Texas at Austin for his undergraduate degree. He is a member of the Texas Trial Lawyers Association, the Houston Bar Association, and the National Association of Criminal Defense Lawyers, among others. He does not lose well. That is a quality you want in a lawyer whose case just got harder.
Lupe Peña is our associate attorney. He has been licensed in Texas since December 6, 2012 — 13+ years. He is also admitted to the Southern District of Texas. Before he joined our firm, Lupe spent years as an insurance-defense attorney at a national defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue claims exactly like yours. He knows how the other side values a file because he used to be the one doing it. He knows which IME doctors the insurers pick, how recorded statements are engineered, how surveillance is deployed, and how the quick settlement check with a release attached is timed to arrive before the medical results do. He now uses that knowledge for injured clients. And Lupe is fluent in Spanish — he conducts full client consultations in Spanish without an interpreter. If your family prays in Spanish, your lawyer should be able to talk to you in Spanish.
We work on contingency. That means we do not get paid unless we win your case. Our fee is 33.33% before trial and 40% if the case goes to trial. The consultation is free. We have live staff 24 hours a day, seven days a week — not an answering service, not a call center, people who work for our firm and can begin the conversation the moment you call.
We have recovered more than $50 million for our clients over our years of practice. That is a firm marketing figure — an aggregate across cases and years. Past results depend on the facts of each case and do not guarantee future outcomes. We tell you the number because you deserve to know the scale of the work we have done, not because we are promising you a result.
What we can promise you is honesty. If the Supreme Court’s ruling has closed the door on your case, we will tell you. If there is a path forward on a different legal theory, we will find it and walk it with you. And if we are not the right fit for your case, we will tell you that too — and point you toward someone who is.
This page is legal information, not legal advice. Every case is different. Contacting us is free and confidential. Hablamos Español.
Call 1-888-ATTY-911. Or call our direct line at (713) 528-9070. The conversation costs nothing. The cost of waiting, in a legal landscape that just shifted under your feet, may be everything.
Our attorneys are ready to talk. Our practice areas cover the full range of toxic tort and catastrophic injury work. And our contact page is live right now.
The Supreme Court closed a door. It did not close every door. Let’s find out which one is still open for you.
